[ Cybrexa Therapeutics raises $6M in Series B ]

Cybrexa Therapeutics  has raised $6 million in Series B funding.

Founded in 2017, Cybrexa Therapeutics is a biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment.

The company will use the fresh money to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).

Funding  Series B
Founded  2017
Country  USA
City  New Haven, Connecticut
Founder / CEO  Per Hellsund
Deal Size  $6M
Investors  Connecticut Innovations
 HighCape Partners
Previous Investors  /